[1]
|
A. E. Jergens, “Inflammatory Bowel Disease: Current Perspectives,” Veterinary Clinics of North America: Small Animal Practice, Vol. 29, No. 2, 1999, pp. 501-521.
|
[2]
|
S. J. Ettinger and E. C. Feldman, “Disease of the Small Intestine,” In: E. D. Hall and A. J. German, Eds., Textbook of Veterinary Internal Medicine, Saunders Co., Philadelphia, 2010, pp. 1526-1572.
|
[3]
|
P. B. Peterson and M. D. Willard, “Protein-Losing Enteropathies,” Veterinary Clinics of North America: Small Animal Practice, Vol. 33, No. 5, 2003, pp. 1061-1082.
doi:10.1016/S0195-5616(03)00055-X
|
[4]
|
M. Cerquetella, A. Spaterna, F. Laus, B. Tesei, G. Rossi, E. Antonelli, V. Villanacci and G. Bassotti, “Inflammatory Bowel Disease in the Dog: Differences and Similarities with Humans,” World Journal of Gastroenterology, Vol. 16, No. 9, 2010, pp. 1050-1056.
doi:10.3748/wjg.v16.i9.1050
|
[5]
|
S. J. Ettinger and E. C. Feldman, “Disease of the Large Intestine” In: K. Allenspach, Ed., Textbook of Veterinary Internal Medicine, Saunders Co., Philadelphia, 2010, pp. 1573-1594.
|
[6]
|
P. A. Kelly, G. J. Burckart and R. Venkataramanan, “Tacrolimus: A New Immunosuppressive Agent,” American Journal of Health-System Pharmacy, Vol. 52, No. 14, 1995, pp. 1521-1535.
|
[7]
|
H. Ogata, T. Matsui, M. Nakamura, M. Iida, M. Takazoe, Y. Suzuki and T. Hibi, “A Randomised Dose Finding Study of Oral Tacrolimus (FK506) Therapy in Refractory Ulcerative Colitis,” An International Journal of Gastroenterology & Hepatology, Vol. 55, No. 11, 2006, pp. 1255-1262. doi:10.1136/gut.2005.081794
|
[8]
|
B. S. Misseghers, A. G. Binnington and K. A. Mathews, “Clinical Observations of the Treatment of Canine Perianal Fistulas with Topical Tacrolimus in 10 Dogs,” Canadian Veterinary Journal, Vol. 41, No. 8, 2000, pp. 623-627.
|
[9]
|
J. D. Griffies, C. L. Mendelsohn, W. S. Rosenkrantz, R. Muse, M. J. Boord and C. E. Griffin, “Topical 0.1% Tacrolimus for the Treatment of Discoid Lupus Erythematosus and Pemphigus Erythematosus in Dogs,” Journal of the American Animal Hospital Association, Vol. 40, No. 1, 2004, pp. 29-41.
|
[10]
|
R. Marsella, C. F. Nicklin, S. Saglio and J. Lopez, “Investigation on the Clinical Efficacy and Safety of 0.1% Tacrolimus Ointment (Protopic) in Canine Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study,” Veterinary Dermatology, Vol. 15, No. 5, 2004, pp. 294-303.
doi:10.1111/j.1365-3164.2004.00397.x
|
[11]
|
A. Berdoulay, R. V. English and B. Nadelstein, “Effect of Topical 0.02% Tacrolimus Aqueous Suspension on Tear Production in Dogs with Keratoconjunctivitis Sicca,” Veterinary Ophthalmology, Vol. 8, No. 4, 2005, pp. 225-232. doi:10.1111/j.1463-5224.2005.00390.x
|
[12]
|
B. J. Stanley and J. G. Hauptman, “Long-Term Prospective Evaluation of Topically Applied 0.1% Tacrolimus Ointment for Treatment of Perianal Sinuses in Dogs,” Journal of the American Veterinary Medical Association, Vol. 235, No. 4, 2009, pp. 397-404.
doi:10.2460/javma.235.4.397
|
[13]
|
K. Allenspach, S. Rufenacht, S. Sauter, A. Gr?ne, J. Steffan, G. Strehlau and F. Gaschen, “Pharmacokinetics and Clinical Efficacy of Cyclosporin Treatment of Dogs with Steroid-Refractory Inflammatory Bowel Disease,” Journal of Veterinary Internal Medicine, Vol. 20, No. 2, 2006, pp. 239-244. doi:10.1111/j.1939-1676.2006.tb02852.x
|
[14]
|
S. Todo, Y. Ueda, J. A. Demetris, O. Imventarza, M. Nalesnik, R. Venkataramanan, L. Makowka and T. E. Starzl, “Immunosuppression of Canine, Monkey, and Baboon Allografts by FK 506: With Special Reference to Synergism with Other Drugs and to Tolerance Induction,” Surgery, Vol. 104, No. 2, 1988, pp. 239-249.
|
[15]
|
T. Fujisawa, Y. Saitoh, N. Urabe, T. Takeda, Y. Sekine, M. Baba and Y. Yamaguchi, “Dose Study of the Immunosuppression of FK 506 in Canine Lung Allo-Transplantation,” Surgery Today, Vol. 23, No. 4, 1993, pp. 338-343. doi:10.1007/BF00309052
|
[16]
|
S. Sakuma, Y. Higashi, N. Sato, T. Sasakawa, T. Sengoku, Y. Ohkubo, T. Amaya and T. Goto, “Tacrolimus Suppressed the Production of Cytokines Involved in Atopic Dermatitis by Direct Stimulation of Human PBMC System (Comparison with Steroids),” International Immunopharmacology, Vol. 1, No. 6, 2001, pp. 1219-1226.
doi:10.1016/S1567-5769(01)00059-5
|
[17]
|
R. Kano, K. Okabayashi, Y. Nakamura, K. Fujiwara, A. Hasegawa and Y. Sasaki, “Systemic Treatment of Sterile Panniculitis with Tacrolimus and Prednisolone in Dogs,” Journal of Veterinary Medical Science, Vol. 68, No. 1, 2006, pp. 95-96. doi:10.1292/jvms.68.95
|
[18]
|
K. Allenspach, P. J. Bergman, S. Sauter, A. Gr?ne, M. G. Doherr and F. Gaschen, “P-Glycoprotein Expression in Lamina Propria Lymphocytes of Duodenal Biopsy Samples in Dogs with Chronic Idiopathic Enteropathies,” Journal of Comparative Pathology, Vol. 134, No. 1, 2006, pp. 1-7. doi:10.1016/j.jcpa.2005.06.003
|
[19]
|
S. Masuda and K. Inui, “An Up-Date Review on Individualized Dosage Adjustment of Calcineurin Inhibitors in Organ Transplant Patients,” Pharmacology & Therapeutics, Vol. 112, No. 1, 2006, pp. 184-198.
doi:10.1016/j.pharmthera.2006.04.006
|
[20]
|
K. Suzuki, K. Saito, S. Tsujimura, S. Nakayamada, K. Yamaoka, N. Sawamukai, S. Iwata, M. Nawata, K. Nakano and Y. Tanaka, “Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-Glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis,” The Journal of Rheumatology, Vol. 37, No. 3, 2010, pp. 512-520. doi:10.3899/jrheum.090048
|
[21]
|
S. Tsujimura, K. Saito, S. Nakayamada, K. Nakano, J. Tsukada, K. Kohno and Y. Tanaka, “Transcriptional Regulation of Multidrug Resistance-1 Gene by Interleukin-2 in Lymphocytes,” Genes to Cells, Vol. 9, No. 12, 2004, pp. 1265-1273.
doi:10.1111/j.1365-2443.2004.00803.x
|